AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9766255
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rh-GH) 0.5-1 IU/day s.c., bedtime (n=8)
Trial: 3041874
Drug: Plasmapheresis (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis (10 ml plasma/kgbw) using a Haemonetics separator (PCS) after premedication before anaesthesia.
Trial: 26350489
Drug: Autologous adipose-derived
RxNorm normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous adipose-derived stromal vascular fraction (ADSVF) injection
Trial: 24286192
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral MPA (10 mg daily for 6 months)
Trial: 24286192
Drug: Cyclic oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic oral MPA (10 mg for 10 days per cycle for 6 months)
Trial: 24330904
Drug: EPA/DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA supplementation as monotherapy (n = 125)
Trial: 24330904
Drug: EPA/DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA supplementation as adjunctive to conventional antidepressants (n = 33)
Trial: 20957321
Drug: Dydrogesterone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (5 mg)
Trial: 20957321
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus Vitamin D (500 mg calcium + 200 mg vitamin D)
Trial: 18375891
Drug: darbepoetin/iron (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darbepoetin/iron (sodium ferric gluconate 125 mg IV weekly for the first 6 weeks)
Trial: 16753767
Drug: L-arginine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (20 g/500 mL) administered via i.v. infusion for 4 consecutive days
Trial: 16753767
Drug: L-arginine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (in subgroup not receiving antihypertensive drugs)
Trial: 16753767
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in subgroup not receiving antihypertensive drugs)
Trial: 9554154
Drug: Western blot
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western blot method for detecting antibodies against rotavirus proteins
Trial: 7699621
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (MTX) therapy
Trial: 29074041
Drug: Sham operation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham operation with water for injection
Trial: 27493136
Drug: Empagliflozin 12.5
RxNorm normalized name: empagliflozin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 12.5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Trial: 27493136
Drug: Empagliflozin 12.5
RxNorm normalized name: empagliflozin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 12.5 mg b.i.d. + Metformin 500 mg b.i.d.
Trial: 27493136
Drug: Empagliflozin 5
RxNorm normalized name: empagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Trial: 27493136
Drug: Empagliflozin 5
RxNorm normalized name: empagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 5 mg b.i.d. + Metformin 500 mg b.i.d.
Trial: 27493136
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg q.d.
Trial: 27493136
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg q.d.
Trial: 27493136
Drug: Metformin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1,000 mg b.i.d.
Trial: 22050786
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg b.i.d.
Trial: 23761968
Drug: RSDM+ (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74)
Trial: 23761968
Drug: RSDM (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSDM (monthly risedronate 150 mg alone, n = 76)
Trial: 18544983
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy (total doses of 60 Gy with single doses of 2 Gy)
Trial: 11071188
Drug: Sodium cromoglicate
RxNorm normalized name: Sodium cromoglicate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglicate by inhalation
Trial: 28646587
Drug: Mini-catheter for
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-catheter for local anesthetic injection (chirochaine 0.125% w/v; 20 mL bolus before consciousness, followed by three consecutive injections of 20 mL each at 8, 16, and 24 hours post-surgery)
Trial: 24953576
Drug: Glycerin suppository
RxNorm normalized name: Leader Pediatric Glycerin Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin suppository (1g) once a day from day‐2 to day‐14 of life
Trial: 24953576
Drug: No suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No suppository
Trial: 21546099
Drug: Daily vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vardenafil 10mg
Trial: 15991553
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy with Novo‐Helisen Depot allergy vaccines for 3 years
Trial: 12912694
Drug: Elective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective treatment (enucleation or eye-conserving radiotherapy)
Trial: 6119096
Drug: bunitrolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bunitrolol (10 mg)
Trial: 26509682
Drug: Muscle-Energy Techniques
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle-Energy Techniques (MET) - 2 treatment sessions per week for 6 weeks
Trial: 17183623
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of disease modifying antirheumatic drugs (DMARD; COMBI)
Trial: 15215224
Drug: Imipenem/cilastatin (1000/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (1000/500 mg) instilled
Trial: 15215224
Drug: Tobramycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (200 mg) instilled
Trial: 557329
Drug: Inhalation provocation
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation provocation tests with formalin
Trial: 30851499
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided erector spinae plane (ESP) block with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Trial: 30851499
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided Quadratus Lumborum Block (QLB) with 0.5 ml/kg 0.25% bupivacaine (max 20 ml)
Trial: 26506582
Drug: Guanfacine Extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine Extended Release (GXR) 1-7 mg per day
Trial: 22974284
Drug: Optimized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized formulation (CCT T8) with core tablet (C8) and mannitol, lag time of 6 hrs before immediate release of drug.
Trial: 22974284
Drug: Optimized solid
RxNorm normalized name: Corydalis solida whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized solid dispersion (S9) used for formulating optimized core tablet formulation (C8).
Trial: 21300933
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus CAPIRI (irinotecan 200 mg/m(2), capecitabine 800 mg/m(2) twice daily)
Trial: 21300933
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus CAPOX (oxaliplatin 130 mg/m(2), capecitabine 1,000 mg/m(2) twice daily)
Trial: 16989024
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream applied 5 or 7 days a week for six weeks
Trial: 16989024
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream applied 5 times a week
Trial: 16989024
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream applied daily
Trial: 16989024
Drug: Surgical excision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical excision (standard treatment)
Trial: 12628884
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (MA) 160 mg (8 mL)
Trial: 12628884
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution 8 mL)
Trial: 8165613
Drug: Factor V
RxNorm normalized name: Factor V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor V deficiency and specific inhibitors of factor V
Trial: 24656153
Drug: 10‐mg generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg generic formulation (test)
Trial: 24656153
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation (reference)
Trial: 20391081
Drug: 6.4% carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% carbohydrate-electrolyte solution
Trial: 20391081
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (8 ml x kg BM(‐1))
Trial: 17922561
Drug: Naloxone (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (continuous infusion)
Trial: 12706638
Drug: Reviparin-sodium (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reviparin-sodium (low molecular weight heparin), administered twice daily.
Trial: 1912675
Drug: First chemotherapy
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First chemotherapy (105 women)
Trial: 1912675
Drug: Breast conservation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conservation therapy (64 women)
Trial: 1912675
Drug: Self-evaluation by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-evaluation by 64 women one year after treatment
Trial: 1912675
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (78 women)
Trial: 6874413
Drug: Safflower seed
RxNorm normalized name: SAFFLOWER SEED
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower seed oil (60 ml/d)
Trial: 10896014
Drug: Aspirin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (900 mg)
Trial: 30831478
Drug: Personalized modular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized modular treatment based on cognitive-behavioral therapy
Trial: 24158227
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (8-week treatment)
Trial: 22999073
Drug: Abciximab treatment
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab treatment in group A (additional platelet inhibition)
Trial: 22999073
Drug: Conventional anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anticoagulation with heparin in group C1 (control group)
Trial: 22999073
Drug: Conventional anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anticoagulation with heparin in group C2 (control group)
Trial: 20393175
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (infliximab + azathioprine)
Trial: 12351526
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of GnRH agonist administration for 1 week after hCG injection
Trial: 7423170
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulfate (220 mg, three daily doses)
Trial: 23218813
Drug: Supplemental parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental parenteral nutrition (SPN)
Trial: 28873109
Drug: Clindamycin cream
RxNorm normalized name: clindamycin Vaginal Cream
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin cream 0.3% once daily
Trial: 28873109
Drug: Clindamycin cream
RxNorm normalized name: clindamycin Vaginal Cream
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin cream 1% once or twice daily
Trial: 28873109
Drug: Clindamycin gel
RxNorm normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin gel 1% twice daily
Trial: 27313086
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine group (six courses of alternating R-CHOP or R-DHAP followed by high-dose cytarabine-containing conditioning regimen and ASCT)
Trial: 27313086
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine group
Trial: 19616668
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg/day, up titrated to 40 mg/day
Trial: 19616668
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/day, up titrated to 10 mg/day
Trial: 11401925
Drug: Folate supplementation
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate supplementation (5 mg daily for 1 year)
Trial: 9479360
Drug: Adjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant immunotherapy with tularemia booster (TB) and anticoagulant treatment (fibrinolysin, pelentan, and aspirin)
Trial: 9479360
Drug: TB inoculation
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB inoculation without anticoagulants (control group 2)
Trial: 3604886
Drug: Bipolar noncapturing
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bipolar noncapturing conditioning stimuli (Sc) with pulse widths of 2 or 9 msec and strengths of twice diastolic threshold and 10 MA
Trial: 3604886
Drug: Unipolar cathodal
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unipolar cathodal noncapturing conditioning stimuli (Sc) with pulse widths of 2 or 9 msec and strengths of twice diastolic threshold and 10 MA
Trial: 29718968
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.3 g·kg‐1 body weight)
Trial: 28473520
Drug: Monthly sanitary
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly sanitary pads
Trial: 25732222
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 125 ml ONS (2.4 kcal/ml)/d for 12 weeks
Trial: 20978528
Drug: High-fat yogurt
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat yogurt supplement
Trial: 20978528
Drug: Low-fat yogurt
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat yogurt supplement
Trial: 12965979
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy with ACE inhibitors
Trial: 12965979
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy without ACE inhibitors
Trial: 2223358
Drug: Prolonged administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged administration of 1% isoflurane (5 patients)
Trial: 21159081
Drug: Home-based management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based management of malaria + Seasonal intermittent preventive treatment (IPTc) with AS+AQ
Trial: 21159081
Drug: Home-based management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based management of malaria + Seasonal intermittent preventive treatment (IPTc) with AS+AQ (only children who received all three courses of IPTc)
Trial: 19809023
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin (BLF) 100 mg/d
Trial: 19809023
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin (BLF) 100 mg/d plus Lactobacillus rhamnosus GG (LGG) 6 x 10(9) colony-forming units/d
Trial: 7845753
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone (65 mg/kg/day once daily, Group A, n = 25)
Trial: 7845753
Drug: Oral cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefixime (10 mg/kg/day divided every 12 hours, Group B, n = 25)
Trial: 7845753
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone (Group A)
Trial: 7845753
Drug: Oral cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefixime (Group B)
Trial: 26257323
Drug: Closed-loop therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop therapy with standard prandial insulin boluses
Trial: 26257323
Drug: Closed-loop therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop therapy with prandial boluses reduced by 25%
Trial: 21859656
Drug: Soy drink
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy drink (240 cc)
Trial: 19706088
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil cream applied once or twice daily under occlusion for 6 weeks
Trial: 18257271
Drug: Migu tablet
RxNorm normalized name: Pseudomonas aeruginosa (schroeter, 1872) migula, 1900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migu tablet (MG)
Trial: 2470310
Drug: Cisplatin, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin, 80 mg/m2 alone (CDDP regimen)
Trial: 2470310
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (MOB-P: vincristine 1 mg, methotrexate 10 mg/m2 d 1, 2, 3, bleomycin 10 mg/m2 d 1, 2, 3)
Trial: 2470310
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (MOB-P)
Trial: 31605797
Drug: Pemetrexed +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed + Gefitinib (P+G)
Trial: 29844250
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (Control Group C)
Trial: 28802634
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration in RS group
Trial: 28802634
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration in NS group
Trial: 9349079
Drug: Prophylactic intravenous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intravenous ephedrine 0.25 mg.kg‐1
Trial: 9349079
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid preloading with Hartmann's solution 20 ml.kg‐1
Trial: 8223792
Drug: Placebo (current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (current therapy)
Trial: 3707815
Drug: Acyclovir tablets
RxNorm normalized name: Acyclovir Tablets
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir tablets (2 X 200 mg)